During the athletics competition on August 8, an Olympic runner collapsed after receiving medication intended to address post-race symptoms, but later determined by officials to be the wrong drug. The incident occurred shortly after the athlete finished a middle-distance event and reported dizziness and nausea to medical personnel stationed near the mixed zone. According to multiple reports from the scene, event medical staff administered a medication before the athlete’s condition acutely worsened and they lost consciousness. On-site medics initiated emergency protocols, performed initial assessment and stabilization, and called for an ambulance. The athlete was transported to a local hospital for further evaluation and observation; team officials said the athlete was conscious and responsive en route and remained under care. Organizers and the athlete’s national federation confirmed they had opened an inquiry to determine how the incorrect medication was given, whether established medical protocols were followed, and whether the error was due to mislabeling, miscommunication, or an administration mistake. Event medical providers at large multisport competitions typically use standardized medication kits and triage procedures, but investigators noted that crowded, high-pressure environments can increase the risk of human error. The exact medication administered and the intended drug have not been publicly confirmed by authorities at the time of reporting. Medical privacy restrictions limit the release of detailed clinical information, and neither the athlete’s name nor specific medical records have been disclosed by teams or organizers. Statements from the organizing committee indicated cooperation with local health authorities and the athlete’s delegation to review medical logs, witness statements and video where available. The national federation issued a brief statement expressing concern for the athlete’s health and requesting a full accounting of the circumstances from event medical leadership. Sports medicine experts noted that wrong-medication incidents, while uncommon at major events with experienced medical teams, can occur when medications have similar packaging or when nonstandard workflows are used in temporary medical facilities. Immediate priorities in such cases are to stabilize the patient, identify the substance administered, and provide appropriate antidotes or supportive care if needed. Longer-term measures commonly include process reviews, retraining, and changes to inventory and labeling practices to reduce recurrence risk. Race officials said they would review accreditation and access controls for medical areas, inventory management of pharmaceuticals, and whether any contributing factors—such as fatigue among staff, language barriers, or equipment layout—played a role. The event’s medical director told media that a formal report would be completed once hospital findings and internal reviews were available. The athlete’s condition was described as stable by team representatives later the same day, though organizers emphasized that hospital observation would continue to rule out delayed effects. No disciplinary or criminal findings had been announced publicly at the time of reporting. This incident raises questions about patient safety protocols at large sporting events and underscores the importance of rigorous medication handling standards, transparent investigation procedures, and prompt communication with the athlete and their delegation. Organizers have pledged to share findings when inquiries conclude and to implement recommended changes if procedural lapses are identified. Until official results of the investigation and hospital reports are released, specific details about the medication error remain unconfirmed.